Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Burns ; 33(3): 372-5, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17218059

RESUMEN

This study was aimed to alert the hazard of accidental adverse reactions of photochemotherapy (Psoralen-UVA or PUVA) that has been used in the treatment for some skin diseases and commercially for cosmetic tanning. Aside from the predictable side effects of PUVA such as erythema and itching, the accidental adverse reactions such as extensive burns could occasionally occur. Our observations indicated that six cases resulted from mistakes of medical personnel, and six other cases resulted from unsupervised mistakes of patients. The conditions that needed photochemotherapy were seven cases of vitiligo, three cases of psoriasis and two cases of tanning. The accidental overdose of UV radiation was about 3-10 times the empirically normal dose. Five of our patients were supposed to undergo topical PUVA, but they were irradiated at the dose of oral PUVA. One patient applied 8-methoxypsoralen (8-MOP) cream together with taking 5-methoxypsoralen (5-MOP) tablets for oral PUVA. Three other patients enjoyed sunbathing 1-3h shortly after finishing PUVA. A young couple chose 5-MOP to enhance tanning and sunbathed about 1h later. When another patient resumed PUVA in a 6-month cessation, he was exposed at a previous dose instead of a starting dose. Erythema and blisters of second degree burns developed in all our cases, 36-72h after PUVA, with 5-25% of body surface involved. Among the 12 patients, 3 were admitted and 9 were treated on an outpatient basis. All patients recovered in 1-3 weeks with no skin graft or no significant sequelae except post-inflammatory hyperpigmentation.


Asunto(s)
Quemaduras/etiología , Furocumarinas/efectos adversos , Terapia PUVA/efectos adversos , Fármacos Fotosensibilizantes/efectos adversos , Traumatismos por Radiación/etiología , Adolescente , Adulto , Niño , Femenino , Humanos , Masculino , Persona de Mediana Edad , Psoriasis/terapia , Dosis de Radiación , Vitíligo/terapia
2.
J Korean Med Sci ; 17(5): 655-9, 2002 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12378018

RESUMEN

The investigation was aimed to determine prognostic factors related to postherpetic neuralgia (PHN), and treatment options for preventing PHN. The data showed 34 (17.0%) out of 188 patients with herpes zoster had severe pain after 4 weeks, and 22 (11.7%) after 8 weeks, compared with 109 (58.0%) at presentation. The age (>/=50 yr), surface area involved (>/=9%), and duration of severe pain (>/=4 weeks) might be the main factors that lead to PHN. On the other hand, gender, dermatomal distribution, accompanied systemic conditions, and interval between initial pain and initiation of treatment might not be implicated in PHN. The subjects were orally received antiviral (valacyclovir), tricyclic antidepressant (amitriptyline), and analgesic (ibuprofen) as the standard treatment in the group 1. In addition to the standard medication, lidocaine solution was sub- and/or perilesionally injected in the group 2, while lidocaine plus prilocaine cream was topically applied to the skin lesions in the group 3. The rates of PHN in the 3 treatment groups were not significantly different, suggesting adjuvant anesthetics may not be helpful to reduce the severity of pain.


Asunto(s)
Aciclovir/análogos & derivados , Herpes Zóster/complicaciones , Neuralgia/etiología , Valina/análogos & derivados , Aciclovir/administración & dosificación , Adolescente , Adulto , Anciano , Amitriptilina/administración & dosificación , Antiinflamatorios no Esteroideos/administración & dosificación , Antidepresivos Tricíclicos/administración & dosificación , Antivirales/administración & dosificación , Niño , Quimioterapia Combinada , Femenino , Herpes Zóster/tratamiento farmacológico , Herpes Zóster/fisiopatología , Humanos , Ibuprofeno/administración & dosificación , Masculino , Persona de Mediana Edad , Neuralgia/tratamiento farmacológico , Neuralgia/fisiopatología , Neuralgia/prevención & control , Pronóstico , Factores de Tiempo , Valaciclovir , Valina/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA